Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
10 /100
LOW RISK
Score updated Aug 28, 2026

ALNY — Alnylam Pharmaceuticals, Inc. Dilution Risk Tracker

Track ALNY dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ALNY — Get alerts when the score changes →

As of August 28, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) has a DilutionWatch DilutionScore of 10/100, rated LOW dilution risk. Alnylam Pharmaceuticals, Inc. has a market capitalization of $40.32B, 133.81M shares outstanding, 796 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
20
💰 Cash Runway
0
📊 Float Risk
2
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for ALNY.
🔔 Track ALNY — Get forecast alerts →

Market Data

Market Cap$40.32B
Shares Outstanding133.81M
Float132.95M
Cash$1.71B
Debt$677.72M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 2.8% shares (2026Q1 vs prior)
796 institutional holders · 144.53M shares
#1 FMR LLC 14.58M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 11.89M shares
#3 Capital World Investors 10.80M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest4.80M
Days to Cover2.2
% of Float3.6%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2025-12-31
3 FORM3 2026-04-07
4 INSIDER TRANSACTION 2026-03-06
4 INSIDER TRANSACTION 2026-03-04
4 INSIDER TRANSACTION 2026-03-04
Full SEC filing analysis available with free account

Recent News

No recent news

Factual ALNY Dilution Snapshot

Alnylam Pharmaceuticals, Inc. (ALNY) has a DilutionScore of 10/100, rated Low dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track ALNY Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ALNY — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for ALNY
ALNY FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.